{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:11:35Z","timestamp":1788869495864,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":1642,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Center for Cancer Research, National Cancer Institute, Intramural Research Program"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.bbmt.2010.10.031","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T04:13:07Z","timestamp":1288671187000},"page":"S94-S100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S","title":["Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"17","author":[{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.10.031_bib1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2010.04.004","volume":"16","author":"Pavletic","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1073\/pnas.87.2.563","article-title":"Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction","volume":"87","author":"Sawyers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2010.10.031_bib3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.leu.2402550","article-title":"Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation","volume":"16","author":"P\u00e9rez-Sim\u00f3n","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.031_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000077564","article-title":"Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning","volume":"112","author":"Shimoni","year":"2004","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3324\/haematol.2009.010843","article-title":"Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia","volume":"95","author":"Elorza","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2010.10.031_bib6","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/bmt.2008.185","article-title":"Minimal residual disease diagnostics in myeloid malignancies in the post transplant period","volume":"42","author":"Bacher","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"ALL-REZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib10","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.25.022106.141606","article-title":"Immunobiology of allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Welniak","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1365-2141.1997.4683272.x","article-title":"The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation","volume":"99","author":"Raanani","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/sj.leu.2401581","article-title":"Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children","volume":"13","author":"Bader","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.031_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2010.06.008","volume":"16","author":"Kr\u00f6ger","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.exphem.2006.01.011","article-title":"Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly-sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma","volume":"34","author":"Kr\u00f6ger","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib16","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.V85.9.2632.bloodjournal8592632","article-title":"Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients","volume":"85","author":"Radich","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib17","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bbmt.2010.07.001","volume":"16","author":"Kr\u00f6ger","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib20","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib21","first-page":"201","article-title":"Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results","volume":"14","author":"Miyamura","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0140-6736(90)92414-D","article-title":"Prediction of clinical relapse after bone-marrow transplantation by PCR for Philadelphia-positive acute lymphoblastic leukaemia","volume":"336","author":"Miyamura","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2010.10.031_bib23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood.V81.4.1089.1089","article-title":"Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients","volume":"81","author":"Miyamura","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib24","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V79.5.1366.1366","article-title":"Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation","volume":"79","author":"Miyamura","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1349-7006.2007.00521.x","article-title":"Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions","volume":"98","author":"Akatsuka","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bbmt.2010.10.031_bib26","doi-asserted-by":"crossref","unstructured":"Warren EH, Fujii N, Akatsuka Y, et\u00a0al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood;115:3869-3878.","DOI":"10.1182\/blood-2009-10-248997"},{"key":"10.1016\/j.bbmt.2010.10.031_bib27","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","article-title":"Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2010.10.031_bib29","first-page":"2415","article-title":"Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"30","author":"Nishiwaki","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bbmt.2010.10.031_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2009.1.371","article-title":"Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)","author":"Ottmann","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2010.10.031_bib31","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib32","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.bbmt.2009.07.016","article-title":"Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review","volume":"15","author":"Koreth","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.031_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.10.031_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.031_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3816\/CLK.2009.n.010","article-title":"Salvage of donor graft with decitabine and maintenance post allogeneic stem cell transplantation in myelodysplastic\/myeloproliferative disease: a case report","volume":"3","author":"Raptis","year":"2009","journal-title":"Clin Leuk"},{"key":"10.1016\/j.bbmt.2010.10.031_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.exphem.2003.09.021","article-title":"Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival","volume":"32","author":"Khouri","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.10.031_bib39","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2008.08.010","article-title":"Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen","volume":"14","author":"Kennedy-Nasser","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.bbmt.2010.02.025","article-title":"Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"16","author":"Bishop","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.bbmt.2010.02.005","volume":"16","author":"Miller","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbmt.2010.03.002","volume":"16","author":"Cairo","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2010.05.005","volume":"16","author":"Alyea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.031_bib44","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110004829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110004829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:38:46Z","timestamp":1761057526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110004829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1083879110004829"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.031","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}